Tag Archives: Geulah Livshits

Arbutus Biopharma (ABUS) Receives a Rating Update from a Top Analyst

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report). The company’s shares closed last Friday at $4.08. According to TipRanks.com, Livshits is a top 100 analyst with an

Chardan Capital Sticks to Their Buy Rating for Cabaletta Bio (CABA)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Cabaletta Bio (CABA – Research Report) today and set a price target of $21.00. The company’s shares closed last Monday at $12.48. According to TipRanks.com, Livshits is a top 100

Rocket Pharmaceuticals (RCKT) Gets a Buy Rating from Chardan Capital

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company’s shares closed last Tuesday at $35.16. According to TipRanks.com, Livshits is a top 100 analyst with an

Chardan Capital Keeps Their Buy Rating on Arbutus Biopharma (ABUS)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) on August 23. The company’s shares closed last Monday at $3.38. According to TipRanks.com, Livshits is a top 100 analyst with an average return

Achilles Therapeutics (ACHL) Received its Third Buy in a Row

After Oppenheimer and Piper Sandler gave Achilles Therapeutics (NASDAQ: ACHL) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Achilles Therapeutics today and set a price

Chardan Capital Sticks to Their Buy Rating for Immatics (IMTX)

In a report issued on April 1, Geulah Livshits from Chardan Capital reiterated a Buy rating on Immatics (IMTX – Research Report). The company’s shares closed last Thursday at $11.64. According to TipRanks.com, Livshits is a top 100 analyst with